27 Aug 2014 Posted in ABPI statement By Press Office
This additional funding will enable many more patients in England to continue to benefit from innovative new cancer medicines that they otherwise would not have been able to receive.
Commenting on the announcement, ABPI Chief Executive Stephen Whitehead said:
“We recognise that NICE frequently struggles with assessing the value of cancer and specialised medicines, hence the establishment of the CDF by the Coalition Government as a measure to solve the immediate problem. Whilst the CDF continues to have an incredibly positive impact for NHS cancer patients, and we welcome this latest cash injection, however it is only a short term solution and ultimately the NICE value assessment process needs to be reformed urgently so that more innovative cancer medicines can routinely be made available for NHS patients. This includes the development of sustainable aligned solutions involving NICE, NHS England and the industry working together.
“We are keen to see the detail of the proposals set out by NHS England in order to evaluate them fully and the ABPI looks forward to working with NHS England, NICE and patient groups to ensure that NHS patients can continue to get access to all modern cancer and specialised medicines and that broader system reform can be achieved as quickly as possible”.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811